you are the only one on this board whom i see has a somewhat reasonable target price . for the uninitiated. please have a look at pharmacyclics which i still own 1600 shares. this one is for keeps. $60-100.
the key takeaway hypothesis is sapacitabine has a good response to ovarian cancer (tumor) on top of AML . there;s something about the main ingredient in there that works . no additional R&D . 1 drug multiple applications. Nice
trade based on the facts .the cards on the table. i remember pcyc was getting dumped big time from 2008-2010. look where is it now. there's bound to be major major overhead supply when we have consolidated for ages in the $3s
i'm in . half a century so far. its a waiting game . will add on for a mo-mo shorty squeeze if it can clear $12.5.
market makers are just going to keep working it lower and attribute it to the govt shutdown , debt ceiling etc. those who are not in it for the long term should just get out. short term holders should just step aside . wait for your breakout signal at $12.
It was the same story at pharmacyclics. Pcyc. History is the best teacher. 50 m market cap when all faith was lost and it looked like they needed more cash. selling for 9bln market cap now pending a marketable drug. Theres something with sapacitabine that works. Be it aml or tumors at either end of the spectrum. While the risk reward is fantastic just put some patient money in there to work and get back to your day job
nobody can say for sure how this stock will turn out in 2014 or even tomorrow. its just a game of chance. but the facts are on the table. wouldn't be surprised to see it fall further ; or market makers working it lower dumping from left pocket to right pocket.
Ariad plummets 70% after drug test patients have serious clotting issues
October 9, 2013, 11:38 AM
By Russ Britt
Investors dropped their shares of Ariad Pharmaceuticals like a bag of rocks Wednesday after the company said it was putting a hold on new patient enrollment for tests on its leukemia drug Iclusig. The reason? A higher number of patients than expected experienced serious circulatory blockages within two years after taking the medication.
Ariad ARIA -69.66% shares plummeted more than 70% to $4.93, losing $12.21 apiece. Ariad said it was working with the U.S. Food and Drug Administration on how to handle the events in Iclusig testing.
The company said after two years of follow-up research on patients taking the drug, 11.8% suffered serious arterial thrombosis, or blood clots. Of those, 6.2% experienced cardiovascular trouble, another 4% suffered vascular issues of the brain and 3.6% had peripheral vascular trouble. Some patients had more than one type of issue, the company said. After 11 months of follow-up, the percentage of those experiencing similar issues stood at 8%.
Another 2.9% experienced serious venous occlusion, or vein blockages, after 24 months, compared with earlier findings of 2.2%. And a total of 20% of the test subjects experienced either serious or non-serious artery and vein troubles after receiving treatment.
Ariad said in a press release that testing would continue on patients in clinical trials, but future patients will be screened to exclude those who have experienced blood clots severe enough in the past to result in a heart attack or stroke.
ariad's about a $3bln market cap company just yesterday. CYCC's sapacitabine AML proposition is working fine thank you.
ARIAD's inclusig is a direct competitor to sapacitabine in AML . ARIA is 1 step behind CYCC and 3bln richer in market cap yesterday before these blood clotting issues . fools
you don't have to repeat this every single day. poor b. bashing a 60m market cap stock predicting it will be cut in half. aint' got nothing better to do .
just a few retail buying now. nothing to cheer. . line in the sand is $12 . that's when the shorts start to buy back. $1 downside $50 upside . i'm sure the shorties are great with their math.
feels like november's short interest will be up again . probably around 2 mln shares. line in the sand of shorties should be $12. sellers are just market makers or shorties. long bag holders are all in the $20-50 range and watching apple stock now.
say you are the big boutique fund. flashy trader who managed to short the entire 2 mln shares out there stated as short interest on nasdaq at $4.3 average the last month . Is it worth the risk to take for a $60mln market cap company? $1 bln gold mining stock or a $178b BHP might just let you breathe easier . and you don't have to check back the stock price for this guy or yahoo boards every 5 mins